|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.62 USD | -0.32% |
|
-3.45% | -31.09% |
| 07-17 | EyePoint Pharmaceuticals Agrees to Settle US False Claims Act Allegations | MT |
| 07-16 | Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target | MT |
Company Valuation: EyePoint, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 414.9 | 119.3 | 1,088 | 522.7 | 1,513 | 1,061 | - | - |
| Change | - | -71.25% | 811.96% | -51.95% | 189.37% | -29.82% | - | - |
| Enterprise Value (EV) 1 | 414.9 | 119.3 | 806.6 | 423 | 1,411 | 767.1 | 897.8 | 263 |
| Change | - | -71.25% | 576.18% | -47.56% | 233.51% | -45.62% | 17.04% | -70.71% |
| P/E | -6.03x | -1.28x | -12.7x | -3.21x | -5.76x | -3.55x | -4.26x | -5.58x |
| PBR | - | - | 4.26x | 1.25x | 4.37x | 4.25x | 7.37x | 1.57x |
| PEG | - | -0x | 0.4x | -0.1x | -0.2x | -0.3x | 0.3x | 0.2x |
| Capitalization / Revenue | 11.2x | 2.88x | 23.6x | 12.1x | 48.2x | 606x | 32.4x | 4.09x |
| EV / Revenue | 11.2x | 2.88x | 17.5x | 9.77x | 45x | 438x | 27.4x | 1.01x |
| EV / EBITDA | - | - | -77.5x | -3.93x | -6.62x | -2.15x | -2.74x | -5.02x |
| EV / EBIT | -7.51x | -1.51x | -10.7x | -2.9x | -5.8x | -2.34x | -2.87x | -1.49x |
| EV / FCF | -8.26x | -1.78x | -502x | -3.25x | -5.8x | -2.47x | -3.01x | -0.95x |
| FCF Yield | -12.1% | -56.3% | -0.2% | -30.8% | -17.3% | -40.6% | -33.2% | -105% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.03 | -2.74 | -1.82 | -2.32 | -3.17 | -3.566 | -2.972 | -2.27 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 36.94 | 41.4 | 46.02 | 43.27 | 31.37 | 1.752 | 32.76 | 259.6 |
| EBITDA 1 | - | - | -10.4 | -107.6 | -213.3 | -357.3 | -327.2 | -52.44 |
| EBIT 1 | -55.28 | -78.94 | -75.07 | -145.9 | -243.4 | -328.4 | -313 | -177.1 |
| Net income 1 | -58.42 | -102.3 | -70.8 | -130.9 | -232 | -316.2 | -289.2 | -228.2 |
| Net Debt 1 | - | - | -281.3 | -99.7 | -101.8 | -294.3 | -163.6 | -798.4 |
| Reference price 2 | 12.24 | 3.50 | 23.11 | 7.45 | 18.27 | 12.66 | 12.66 | 12.66 |
| Nbr of stocks (in thousands) | 33,894 | 34,083 | 47,074 | 70,160 | 82,787 | 83,841 | - | - |
| Announcement Date | 3/3/22 | 3/2/23 | 3/7/24 | 3/5/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.55x | 437.93x | -2.15x | -.--% | 1.06B | |
| 34.57x | 12.36x | 25.86x | 0.58% | 1,037B | |
| 27.4x | 6.26x | 17.33x | 2.1% | 615B | |
| 33x | 7.49x | 15.4x | 2.71% | 448B | |
| 17.76x | 4.4x | 10.85x | 3.01% | 326B | |
| 21.11x | 5.63x | 13.79x | 2.84% | 293B | |
| 21.21x | 4.47x | 12.37x | 1.97% | 264B | |
| 14.09x | 5.24x | 10.8x | 3.55% | 216B | |
| 24.01x | 6.34x | 11.18x | 2.76% | 198B | |
| -46.95x | 5.62x | 31.09x | 2.53% | 162B | |
| Average | 14.26x | 49.58x | 14.65x | 2.21% | 355.85B | |
| Weighted average by Cap. | 23.95x | 7.88x | 18.20x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EYPT Stock
- Valuation EyePoint, Inc.
Select your edition
All financial news and data tailored to specific country editions
